Premium
Disparities in the use of antineoplastic immunotherapy in pediatric malignant adrenal tumors
Author(s) -
Shoag Jamie M.,
Podda Antonello,
Kobetz Erin N.
Publication year - 2020
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28522
Subject(s) - medicine , quartile , immunotherapy , odds ratio , oncology , food and drug administration , neuroblastoma , cancer , odds , confidence interval , logistic regression , environmental health , biology , genetics , cell culture
Dinutuximab is a costly life‐prolonging immunotherapy for high‐risk neuroblastoma. We used a large pediatric inpatient database to analyze the use of antineoplastic immunotherapy in patients with malignant adrenal tumors 1 year after Food and Drug Administration approval of dinutuximab for high‐risk neuroblastoma. On multivariate modeling, children of Black race (odds ratio [OR] 0.62, P = .04; referent non‐Black) and the lowest ZIP code income quartile (OR 0.74, P = .03; referent wealthier 3 quartiles) were significantly less like to receive antineoplastic immunotherapy. These results suggest substantial disparities in the distribution of a vital therapy in children with advanced cancer.